Story
GERD
Last updated
In one pass Heartburn and acid regurgitation are stomach acid washing back up into the esophagus.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
How reflux happens
Heartburn and acid regurgitation are stomach acid washing back up into the esophagus. Between the stomach and the esophagus sits a one-way valve, the lower esophageal sphincter (LES). The esophagus lies in the chest, where pressure is slightly lower; the stomach lies in the belly, where pressure is positive. It is this valve that normally keeps the acid down.
The valve opens by itself dozens of times a day — a transient lower esophageal sphincter relaxation (TLESR) — so that swallowed air can come up as a burp. Gastroesophageal reflux disease () is usually not a broken valve. The valve opens too often and stays open too long, just when acid is waiting below it. When you stand, gravity pushes the refluxed acid back down. Lie flat and that help is gone; once you are asleep you almost stop swallowing, so the esophagus is no longer rinsed clean.
One kind of chest pain must not be treated as acid: chest pain that is new, chest pain that comes on with exertion, or chest pain with sweating, breathlessness or nausea. Treat it as a possible heart problem first and go to the emergency department now.
The valve opens by itself dozens of times a day — a transient lower esophageal sphincter relaxation (TLESR) — so that swallowed air can come up as a burp. Gastroesophageal reflux disease () is usually not a broken valve. The valve opens too often and stays open too long, just when acid is waiting below it. When you stand, gravity pushes the refluxed acid back down. Lie flat and that help is gone; once you are asleep you almost stop swallowing, so the esophagus is no longer rinsed clean.
One kind of chest pain must not be treated as acid: chest pain that is new, chest pain that comes on with exertion, or chest pain with sweating, breathlessness or nausea. Treat it as a possible heart problem first and go to the emergency department now.
Clinical · What reflux looks like beyond heartburn
How common it is: heartburn is very common, and healthy people get it now and then too. What separates them from people with gastroesophageal reflux disease () is how often and how badly, not whether it ever happens. Being woken at night by burning deserves particular attention. It becomes more common as weight rises: at a above 35, GERD is up to six times as common as at a normal weight, and about two-thirds of pregnant women have heartburn (Katz 2022).Four routes that make it worse, each of which makes the lower esophageal sphincter (LES, the one-way valve between stomach and esophagus) easier to breach:
The valve itself is loose: low resting pressure means a poor basic seal. Scleroderma, some drugs, smoking, alcohol and high-fat meals all loosen it further.Hiatal hernia: part of the stomach slides up into the chest. The valve leaves the grip of the diaphragm and loses its physical support, so transient relaxations (TLESRs) and reflux both become more frequent.Slow stomach emptying: diabetic gastroparesis, overeating or very fatty meals keep pressure in the stomach high, pushing harder upward.High pressure in the belly: obesity, pregnancy, tight clothing and bending over right after a meal all add a push from below.
So not eating in the 2–3 hours before bed and raising the whole head of the bed by 15–20 cm are changes to pressure and gravity, not an old rule of thumb.
What aggravates it falls into three groups: what you eat (high-fat food, chocolate, coffee and strong tea, alcohol, spicy food, tomato, citrus and the like), what you do (lying down after a full meal, big meals and late-night snacks, tight clothes, bending over), and some drugs that loosen the sphincter (nonsteroidal anti-inflammatory drugs, or , some blood-pressure drugs, nitroglycerin and others). Smoking, alcohol and obesity are the long-term background underneath. Triggers differ from person to person; a food diary that finds your own few is more practical than giving up everything on the list.
How it is diagnosed: most people do not need an endoscopy first. For typical heartburn and regurgitation without warning signs, the guideline recommends an 8-week trial of a proton pump inhibitor (, a class of strong acid-suppressing drugs) prescribed by a doctor, once a day before a meal; if it works, the reflux is treated as such, and then the doctor helps you try stopping the drug (Katz 2022). Warning signs mean you should see a doctor soon, usually for an endoscopy: onset after age 50, difficulty swallowing, weight loss, anemia, black stools or repeated vomiting. Hard-to-treat or atypical cases go on to 24-h pH-impedance monitoring (a thin tube passed through the nose into the esophagus records, over a whole day, how much acid and fluid comes back up) or esophageal manometry.
Complications: the milder ones are esophagitis, ulcers and strictures. The serious one is when years of reflux replace the lining of the lower esophagus with a different kind of cell — Barrett's esophagus. It is the precursor lesion of esophageal adenocarcinoma, but most of it never becomes cancer: Barrett's esophagus without dysplasia progresses to cancer at about 0.05–0.2% a year. Esophageal adenocarcinoma has been one of the fastest-rising cancers in the West for decades. Who should be screened, and how often to recheck, is covered in the chapter Endoscopy checks and chest pain.
Reflux without heartburn: some reflux comes without typical heartburn. Its symptoms are all outside the esophagus, so it is often seen as an ear-nose-and-throat, lung or heart problem.
When refluxed material travels all the way up to the throat and vocal cords, it is called laryngopharyngeal reflux (LPR). Typical signs are a chronic cough, constant throat clearing, hoarseness, a feeling of something stuck in the throat (globus), mucus dripping down the back of the throat, and in some people recurrent vocal-cord granulomas. Many have no heartburn, so they are treated for years as having "chronic pharyngitis" or "allergic rhinitis". Doctors use a look at the larynx and the Reflux Symptom Index (RSI, a symptom questionnaire; a score above 13 is abnormal), but the guideline warns that LPR should not be diagnosed from the look of the larynx alone, and that people without heartburn or regurgitation should have reflux monitoring to confirm reflux before starting a PPI (Katz 2022).
Other signs that may be reflux at work:
A chronic cough, worse at night: some studies attribute 21–41% of chronic cough to reflux, yet PPIs do not help most people with chronic cough (Katz 2022).Asthma that worsens or is hard to control: reflux and asthma often occur together, but in two randomized trials twice-daily PPI did not improve asthma (Katz 2022).Recurrent middle-ear or sinus infections in children: small amounts of refluxed material are drawn up near the Eustachian tube.Acid-eroded tooth enamel and repeated cavities: often first noticed by a dentist.Chronic nasal congestion.Unexplained chest pain: rule out the heart first, then consider reflux.Difficulty swallowing or food getting stuck: a warning sign that requires an endoscopy.
How clinicians tell them apart:
Typical reflux (heartburn plus regurgitation): a doctor usually starts with an 8-week PPI trial.Symptoms outside the esophagus, such as throat symptoms, cough or asthma: look for causes other than reflux first (a strong recommendation in the guideline). With heartburn or regurgitation as well, a doctor may prescribe a trial of twice-daily PPI for 8–12 weeks before more testing; without them, reflux monitoring comes first, and then the decision about a PPI.Chronic cough (no asthma, non-smoker): the 3 most common causes are reflux, cough-variant asthma and upper-airway cough syndrome, and a doctor will test and rule them out one at a time.Recurrent ear infections or cough in a child: do not forget reflux.
Why atypical reflux is hard to diagnose: the symptoms are not specific and overlap with allergy, infection and psychological factors. The look of the larynx alone cannot confirm it. And PPIs help these symptoms outside the esophagus much less than they help heartburn. And many doctors seeing a chronic cough or a throat problem do not think of reflux first.
What you can do:
A cough lasting ≥ 8 weeks, with asthma and upper-airway causes ruled out: if you also have heartburn or regurgitation, discuss a PPI trial with your doctor; if not, ask whether reflux monitoring should come first. Raising the head of the bed and avoiding triggers make sense either way.Recurrent hoarseness or a feeling of something in the throat: have the larynx examined first to rule out other disease, then the same steps.No heartburn does not mean no reflux.
gyawali-2018-acg-gerd
Chapter 2
Long-term PPIs: pros and cons
Proton pump inhibitors () directly block the proton pump on the stomach's parietal cells — the pump that secretes acid — and push acid output very low. For conditions with a clear indication, such as esophagitis, ulcers, Helicobacter pylori eradication and Barrett's esophagus, they are genuinely good drugs.
The trouble is that they work very well and are hard to stop. After long acid suppression, parietal cells multiply to compensate and gastrin (the hormone that drives the stomach to secrete acid) rises. Stop suddenly, and acid briefly rebounds above where it was before treatment, which makes people feel they cannot do without the drug. So the rule is a clear indication, the lowest effective dose and the shortest course that works; if you want to stop, taper slowly under a doctor's guidance. Barrett's esophagus, severe esophagitis and a past bleeding ulcer are situations where long-term treatment is right — do not stop on your own.
The trouble is that they work very well and are hard to stop. After long acid suppression, parietal cells multiply to compensate and gastrin (the hormone that drives the stomach to secrete acid) rises. Stop suddenly, and acid briefly rebounds above where it was before treatment, which makes people feel they cannot do without the drug. So the rule is a clear indication, the lowest effective dose and the shortest course that works; if you want to stop, taper slowly under a doctor's guidance. Barrett's esophagus, severe esophagitis and a past bleeding ulcer are situations where long-term treatment is right — do not stop on your own.
In practice · The cost of long-term PPIs, and tapering
Proton pump inhibitors () were a revolution in the 1980s: they directly block the acid-secreting proton pump (the H+/K+ ATPase) on the stomach's parietal cells and push acid output very low. Omeprazole and the other drugs whose names end in "-prazole" belong to this class. For conditions with a clear indication — esophagitis, peptic ulcer, Helicobacter pylori eradication, Barrett's esophagus — they are genuinely good drugs. But taking one whenever the stomach feels off is very common, and a considerable share of prescriptions have no clear indication.The costs of long-term use (more than a year) come mostly from the fact that stomach acid is useful:
With less acid, the vitamin B12 bound to protein in food cannot be released, so B12 deficiency becomes more likely. A large case-control study (Lam 2013) found that people who had used PPIs for two years or longer had a higher risk of B12 deficiency; this is an observed association.Absorption of calcium, iron and magnesium is affected too, with links to fracture risk, iron-deficiency anemia and low magnesium.With a weaker acid barrier against germs, the risks of Clostridioides difficile colitis and pneumonia rise slightly.There are also associations with chronic kidney disease and dementia, but the data conflict and causation has not been established.
Most of this comes from observational studies. In the one large randomized trial (Moayyedi: 17,598 people, pantoprazole against placebo for 3 years), the groups differed only in enteric infections (1.4% vs 1.0%); so the guideline judges that most harms seen in observational studies probably reflect people on PPIs being sicker to begin with, which the studies could not fully adjust for (Katz 2022). For people with an indication these risks are far smaller than the benefit; for people taking PPIs long-term without one, the risk buys nothing.
Gentler options: an H2-receptor blocker (such as famotidine) has fewer side effects and suppresses acid less strongly than a PPI. It suits mild-to-moderate cases, or serves as a bridge while tapering a PPI. For occasional heartburn, antacids (calcium carbonate, aluminum-magnesium products, alginate) give immediate relief; alginate forms a "raft" on top of the stomach contents that blocks reflux.
Why stopping causes a rebound (the medical term is rebound acid hypersecretion): with long PPI use and less acid, parietal cells multiply to compensate, and feedback pushes gastrin up. Stop suddenly, and those extra cells go back to work under the push of high gastrin, so acid output briefly exceeds its pre-treatment level. People feel "worse than when I started", conclude that they cannot do without a PPI, take it again, and may stay on it for good. It can be seen in healthy people: in a in 120 healthy volunteers (Reimer 2009), after 8 weeks of a PPI followed by stopping, 44% developed acid-related symptoms they had not had before in the next 4 weeks, against 15% in the group that took placebo throughout. Whether symptoms actually increase when patients who already have reflux stop abruptly, the guideline says, still lacks strong evidence (Katz 2022). Stopping PPIs is rarely taught in medical training; most doctors know how to start them, not how to stop.
One common way to taper (set the pace with your doctor; this is common clinical practice, not the only schedule, and it has not been compared in trials):
Weeks 1–2: halve the dose (for example from 20 mg to 10 mg), or take it every other day.Weeks 3–4: reduce further, for example 10 mg every other day.Weeks 5–6: stop the PPI and bridge with famotidine 20 mg at bedtime.Weeks 7–8: take famotidine only when symptoms occur, then stop completely.Throughout: keep strictly to the lifestyle steps (head of the bed raised, triggers avoided, weight loss).
Handling the rebound:
Alginate as needed: it does not change acid, it blocks reflux with a physical raft.Famotidine 20–40 mg at bedtime: it suppresses acid, but after about a month of daily use the body adapts and night-time acid control fades (Katz 2022), so it suits a short bridge.Antacids such as magnesium hydroxide or calcium carbonate as needed: immediate relief.Without a clear indication, do not go back to a PPI.
Vonoprazan · a potassium-competitive acid blocker (P-CAB):
By 2022 it was on the market in China; by 2024 the US FDA had also approved it for erosive esophagitis.Mechanism: it competes with potassium to block the same proton pump reversibly, and unlike a PPI it does not need to be activated by acid first.Trial evidence: in Laine 2023 (a randomized controlled trial in erosive esophagitis, n=1024, against lansoprazole), healing by 8 weeks was 92.9% versus 84.6%. The primary analysis showed vonoprazan was not inferior; superiority was an exploratory analysis. In severe esophagitis (the two worst Los Angeles classes, C and D), healing at week 2 was 17.6 percentage points higher, and maintenance of healing was also better. The benefit showed up mainly in the more severe patients.Pharmacology: faster onset (about 1 day, against 3–5 days for a PPI), no need to take it before a meal, and a longer half-life (about 9 h), which gives better control of acid at night.Concerns: long-term data beyond 2 years are still accumulating. Gastrin rises more, which in theory could make ECL cells in the stomach multiply and raise the risk of carcinoid tumors — this comes from rat data and has not been confirmed in people.Suited to: reflux that does not respond well to a PPI, severe esophagitis, and Helicobacter pylori eradication regimens.
PPI or P-CAB:
For most reflux, a PPI is still the first choice: cheap, with long-term data, and usually enough.Symptoms still severe after a full 8 weeks of PPI, severe esophagitis, or night-time reflux that cannot be controlled: a step up to a P-CAB is reasonable.Do not prescribe a P-CAB by default as a "premium PPI": long-term data, price and availability in each country are still different.
reimer-2009-ppi-rebound
Chapter 3
Endoscopy checks and chest pain
Two things must not be missed. First, years of reflux can replace the lining of the lower esophagus — squamous cells — with columnar cells containing goblet cells. This is Barrett's esophagus. It is the tissue protecting itself, but it carries a risk of cancer, so people who have it should have endoscopies at the intervals guidelines set.
Second, chest pain from reflux travels the same visceral nerve pathway as angina, and the brain cannot easily tell where the pain comes from. Do not assume chest pain is a stomach problem: rule out the heart first, then talk about reflux.
Second, chest pain from reflux travels the same visceral nerve pathway as angina, and the brain cannot easily tell where the pain comes from. Do not assume chest pain is a stomach problem: rule out the heart first, then talk about reflux.
Clinical · Who needs Barrett's screening and checks
What Barrett's esophagus is: after years of irritation by refluxed acid and bile, the squamous lining of the lower esophagus is replaced by a columnar lining containing goblet cells (intestinal metaplasia). The tissue is protecting itself, but the change carries a risk of cancer; it is the only known precursor of esophageal adenocarcinoma.Whether it turns into cancer: some people with long-standing reflux develop Barrett's esophagus, but most Barrett's esophagus never becomes cancer. The American College of Gastroenterology (ACG) 2022 guideline (Shaheen 2022) estimates that Barrett's esophagus without dysplasia progresses to cancer at about 0.05–0.2% a year, and Barrett's with low-grade dysplasia (LGD, cells that have started to look abnormal, but only mildly) at about 0.7% a year. Esophageal adenocarcinoma has been rising in the West for decades, in step with obesity and reflux.
Who should have one screening endoscopy: ACG 2022 suggests (a conditional recommendation, very-low-quality evidence) a single screening endoscopy for people with chronic reflux symptoms plus at least 3 risk factors. The risk factors are male sex, age over 50, White race, smoking, obesity, and a first-degree relative with Barrett's esophagus or esophageal adenocarcinoma. Barrett's esophagus is much less common in women than in men, and women are also less likely to collect enough of these risk factors. The guideline also accepts screening without endoscopy, such as a swallowed sampling sponge that is pulled back out (devices like the Cytosponge), though these are not yet widely available in China.
How often to recheck after diagnosis (ACG 2022):
No dysplasia: the interval depends on segment length, every 3–5 years — every 3 years for segments of ≥ 3 cm and every 5 years for segments < 3 cm (a strong recommendation). Biopsies follow the Seattle protocol: samples from four directions every 1–2 cm.Indefinite for dysplasia: first raise the to twice a day, then repeat the endoscopy within 6 months.Low-grade dysplasia: the guideline favors endoscopic eradication therapy and also accepts surveillance instead: endoscopy at 6 and at 12 months, then yearly.High-grade dysplasia: endoscopic eradication (radiofrequency ablation, RFA, or endoscopic mucosal resection, EMR), not observation alone.
Acid suppression: the guideline suggests at least once-daily PPI (proton pump inhibitor) for people with Barrett's esophagus. This is long-term use with a clear indication, and the benefit outweighs the risk; do not stop because of worries about long-term PPIs.
New tools: chromoendoscopy and narrow-band imaging (NBI) raise the detection rate of dysplasia. Gene or protein marker tests (such as TissueCypher or p53 staining) try to sort progression risk into high and low, but ACG 2022 judged the evidence insufficient and did not recommend them for routine use.
Clinical · Reflux chest pain or angina?
Chest pain from reflux closely mimics angina: both travel along the same visceral sensory nerves (the T1–T4 segments) to the same region of the brain, which finds it hard to tell whether the pain comes from the esophagus or the heart. Never assume that acid regurgitation means .A few terms used in the table: a proton pump inhibitor () is a class of strong acid-suppressing drugs; troponin is a blood marker that rises when heart muscle is damaged; a calcium-channel blocker is a blood-pressure drug that relaxes smooth muscle; esophageal manometry passes a thin tube into the esophagus to measure the pressure and rhythm of its contractions.
| Feature | Reflux chest pain | Angina | Esophageal spasm |
|---|---|---|---|
| Trigger | Heavy meal, lying down, bending | Exertion, emotion, cold | Cold or hot drinks, swallowing |
| Relief | Antacid, sitting up / PPI | Rest + nitroglycerin | Settles by itself, calcium-channel blocker |
| Quality | Burning, acid | Crushing, tight / breathless | Squeezing, spasm |
| Radiation | Upward to the throat | Left shoulder, jaw, left arm | Same as angina (hard to tell apart) |
| Duration | Tens of minutes | 3–15 minutes | Seconds to minutes |
| Sweating, nausea, breathlessness | Rare | Common | Occasional |
| At night | Common when lying flat | Unstable or variant (Prinzmetal) angina | Rare |
| First test | Rule out the heart, then endoscopy or reflux monitoring | ECG + troponin | Rule out the heart, then esophageal manometry |
Red flag · Chest pain: rule out the heart first
Go to the emergency department now, and rule out the heart first, when:You are over 40, the chest pain is new, it comes on with exertion, and it brings sweating, breathlessness or nausea: go to the emergency department now for an electrocardiogram (ECG) and troponin (a blood marker that rises when heart muscle is damaged). Do not assume it is reflux.Angina in women is often atypical: it can show up as burning in the upper belly, back pain or extreme tiredness, so it is more easily mistaken for "a stomach problem".You already have heart disease, or your risk is high (smoking, high blood pressure, diabetes, high cholesterol, family history): even if it feels like reflux, rule out the heart first.
Among people who come to the emergency department complaining of "heartburn", some actually have a heart problem. This is the blind spot in reflux where the gravest mistakes are made.
What to do in practice:
A first episode of chest pain plus any cardiovascular risk factor: ECG and troponin in the emergency department, and coronary CT angiography (CTA) or coronary angiography if needed; only once the heart is ruled out, talk about reflux.The heart already ruled out, plus a clear history of reflux, typical burning, worse lying down and relieved by antacids: it can be treated as reflux, with a trial. For chest pain without heartburn, the guideline suggests objective testing for reflux (endoscopy or reflux monitoring) (Katz 2022).Chest pain that comes on with exercise: ruling out the heart is always the first step.Esophageal spasm (diffuse esophageal spasm, and "nutcracker" esophagus, where contractions have abnormally high pressure): confirmed by esophageal manometry; the choice of drug is the doctor's, who sometimes tries a calcium-channel blocker (such as nifedipine) or nitroglycerin.
Chapter 4
Lifestyle steps and when to use drugs
The strongest levers against reflux are not in a pill bottle. Taking pressure off the belly, raising the whole head of the bed, and eating nothing in the two or three hours before sleep all change the pressure difference and the gravity that push acid upward. Eating and then lying straight down is the most common way people make it worse for themselves.
Proton pump inhibitors () are powerful, but they need a reason. With a clear indication, the benefit outweighs the risk; taken long-term without one, the risk buys nothing. Mild reflux calls for antacids when needed, moderate reflux for a time-limited trial, and hard-to-treat reflux for stronger drugs or surgery.
Proton pump inhibitors () are powerful, but they need a reason. With a clear indication, the benefit outweighs the risk; taken long-term without one, the risk buys nothing. Mild reflux calls for antacids when needed, moderate reflux for a time-limited trial, and hard-to-treat reflux for stronger drugs or surgery.
In practice · Managing reflux step by step
Lifestyle (roughly in order of weight):① Lose weight: for people who are overweight (body mass index, , ≥ 25), this is the step that carries the most weight, because lower pressure in the belly means less push upward; it is also the only lifestyle step the guideline recommends strongly, while the ones below are conditional (Katz 2022). The evidence linking weight and reflux is observational: in more than 10,000 women in the US Nurses' Health Study, Jacobson 2006 found that the higher the BMI, the more common weekly reflux symptoms were, in a dose-dependent way; even among women who started at a normal weight, gaining weight was linked to more reflux. It measured an association between weight and symptoms, not what happens after weight loss.
② Raise the head of the bed by 15–20 cm: not more pillows, but lifting the whole head end of the bed (wood blocks under the legs, or a wedge). It works at night; it does not replace daytime control of what you eat.
③ Nothing to eat in the 2–3 hours before bed, and no late-night snacks: eating and then lying straight down is the most common behavioral cause of reflux.
④ Eat less at a time, and eat slowly: a big meal stretches the stomach, and the valve relaxes by itself — a transient lower esophageal sphincter relaxation (TLESR) — more often.
⑤ Find your own trigger foods: keep a food and symptom diary for 2–4 weeks. Common triggers are high-fat food, chocolate, mint, coffee, tea, alcohol, carbonated drinks, spicy food, tomato and citrus, but they vary from person to person. Alcohol, smoking, chocolate, peppermint and high-fat food do lower sphincter pressure in laboratory studies, but few studies have shown that avoiding them eases reflux (Katz 2022), so find your own rather than giving up the whole list.
⑥ Stop smoking and drink less alcohol: smoking lowers the pressure of the lower esophageal sphincter (LES) and reduces saliva; alcohol relaxes the sphincter directly.
⑦ Sleep on your left side: for anatomical reasons there is less reflux lying on the left than on the right; it helps some people.
⑧ No tight clothing, and no bending over after meals.
Drug tiers:
Mild (1–2 episodes a week): an antacid when needed, or an H2-receptor blocker (H2RA, such as famotidine) when needed.Moderate (≥ 3 episodes a week, affecting daily life): a regular H2RA, or an 8-week trial (once a day, 30–60 minutes before a meal).Severe, or esophagitis seen on endoscopy: a PPI (it heals esophagitis better than an H2RA), then reassessment after a course; the most severe esophagitis, Los Angeles grades C and D, needs long-term maintenance treatment or anti-reflux surgery.Hard to treat: a double dose of PPI, an added H2RA at bedtime (after about a month of daily use it loses effect), an endoscopic evaluation, or a step up to a potassium-competitive acid blocker (P-CAB) such as vonoprazan.
Surgery (for reflux that is hard to treat, with esophagitis, or after years of dependence on PPIs):
Laparoscopic fundoplication (Nissen): the top of the stomach is wrapped around the lower esophagus and stitched, reinforcing the valve.Magnetic sphincter augmentation (LINX): a ring of magnetic beads around the lower esophagus; newer and less invasive.Transoral incisionless fundoplication (TIF): done through an endoscope.Suited to people who have depended on PPIs for a long time, do not want to keep taking them, and have severe reflux confirmed repeatedly on endoscopy.
Gastroesophageal reflux disease is often underestimated and often overtreated. A PPI is powerful, but it is not a stomach pill to take casually. The usual clinical practice is lifestyle as the foundation, and the lowest effective dose of a PPI when there is a clear indication. Whether long-term PPI use is safe depends on the person: with a clear indication, the benefit outweighs the risk; taken long-term without one, the risk buys nothing.
Night-time reflux is the hardest to manage, and the most likely to bring Barrett's esophagus, aspiration, asthma and broken sleep. Why it is worse:
Lying flat, gravity cannot help, so refluxed material stays in the esophagus longer.During sleep, saliva production drops sharply, so the esophagus is less able to rinse itself clean.Once asleep, you also swallow far less, so what comes up is not pushed back down.So the same reflux does more damage to the esophagus at night than in the day.
7 things for night-time reflux (roughly in order of weight):
1. Finish dinner early, at least 2–3 hours before bed (the most important one).
2. Raise the whole head of the bed by 15–20 cm (not pillows): a wedge, or wood blocks under the bed legs.
3. Sleep on your left side: the stomach then sits below the esophagus and gravity helps; lying on the right side or on your back is worst.
4. Take a PPI 30–60 minutes before a meal, not at bedtime (it can only block proton pumps that are working, and eating switches them on); for hard-to-treat cases, add an H2RA at bedtime under a doctor's guidance.
5. Avoid triggers: a high-fat dinner, chocolate, alcohol, drinking a lot of water just before bed.
6. Lose weight: reasoning from the weight-reflux association above, even a modest weight loss may ease night-time reflux; this step has not been measured directly.
7. Use continuous positive airway pressure () if you also have obstructive sleep apnea (): the two often occur together and may make each other worse, and treating the sleep apnea may also reduce night-time reflux.
Night-time aids: a wedge pillow with side-sleeping support helps some people; an adjustable electric bed is a big investment but the most comfortable; a band worn around the neck that presses on the upper esophageal sphincter from outside is a new option for people with throat reflux and small-volume aspiration, with little evidence yet.
Reflux in pregnancy (about two-thirds of pregnant women have heartburn, Katz 2022):
Why: rising progesterone loosens the lower esophageal sphincter, and the growing uterus raises pressure in the belly, pushing reflux upward. It usually starts in the second trimester, is worst in the third, and goes away after delivery.Drugs that can be used in pregnancy: alginate is the safest, working as a physical barrier and hardly entering the blood. Calcium-carbonate antacids can be used and add calcium, but too much can push blood calcium too high (milk-alkali syndrome). Magnesium or aluminum hydroxide antacids are fine short-term; long-term magnesium can cause diarrhea. Famotidine (an H2RA) was category B in the old US FDA pregnancy categories (that letter system has been retired), has good long-term data, and is used for moderate-to-severe reflux. Most PPIs were category B in the old system; omeprazole was listed as category C because of animal data, yet it has the most human pregnancy data. Avoid them in the first 3 months if possible, and use them in mid-to-late pregnancy only after a doctor's assessment.Not recommended in pregnancy: cisapride (withdrawn from the market); baking soda (sodium bicarbonate), because of the sodium load.Without drugs: small, frequent meals (5–6 instead of 3 large ones); sit up for 1 hour after dinner before lying down; sleep on the left side with the head of the bed raised; avoid trigger foods.
Food and symptom diary (keep it for 2–4 weeks): each line records the date, the time of the meal, what you ate, the portion, symptoms 1 hour after eating (score 0–10), symptoms at night (score 0–10), and any medicines taken that day.
How to read it:
After 4 weeks, compare your "bad days" with your "good days" and look at what each group has in common.Do not cut every "theoretical trigger" at once: people differ a lot, and someone may not react to chili at all yet react strongly to chocolate.Triggers are often combinations — dinner at 8 p.m., with alcohol, in a large portion — rather than one food.If your reflux has become chronic, pick the 3–5 most reliable triggers to avoid for the long term and let the rest back in moderation. Do not turn life into a set of rules.
References · 5
- Katz, P. O., Dunbar, K. B., Schnoll-Sussman, F. H., Greer, K. B., Yadlapati, R., & Spechler, S. J. (2022). ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology, 117(1), 27-56. GRADE-rated. Diagnosis: for classic heartburn and regurgitation without alarm symptoms, an 8-week empiric trial of a PPI once daily before a meal (strong, moderate), then an attempt to stop it in responders (conditional, low); endoscopy first for dysphagia or other alarm symptoms (weight loss, GI bleeding) and for multiple Barrett's risk factors (strong, low); chest pain without heartburn, after adequate evaluation to exclude heart disease, calls for objective testing for GERD (conditional, low). Lifestyle: weight loss in overweight and obese patients (strong, moderate); avoiding meals within 2-3 hours of bedtime, avoiding tobacco, avoiding trigger foods and elevating the head of the bed for nighttime symptoms are each conditional, low (the text: alcohol, smoking, chocolate, peppermint and high-fat foods lower LES pressure in the laboratory, but few studies document benefit from avoiding them; several RCTs support head-of-bed elevation or a wedge for nocturnal symptoms). Drugs: PPI 30-60 min before a meal rather than at bedtime (strong, moderate); PPI over H2RA for healing and for maintaining healed erosive esophagitis (strong); maintenance PPI indefinitely or antireflux surgery for LA grade C or D esophagitis (strong, moderate); on-demand or intermittent PPI for non-erosive disease (conditional, low); use the lowest effective dose; rebound acid hypersecretion after stopping has been shown in healthy controls, but strong evidence that symptoms increase after abrupt withdrawal is lacking; bedtime H2RA lost pH control (tachyphylaxis) after a month. Extraesophageal symptoms: look for non-GERD causes first (strong, moderate); without typical heartburn or regurgitation, reflux testing BEFORE PPI therapy (strong, moderate); with typical symptoms as well, consider twice-daily PPI for 8-12 weeks before more testing; LPR should not be diagnosed from laryngoscopy alone; some studies attribute 21-41% of chronic cough to GERD, but PPIs do not help chronic cough in most patients, and two RCTs found no asthma benefit from twice-daily PPI. Safety: in the Moayyedi RCT (17,598 people, pantoprazole 40 mg vs placebo, 3 years) only enteric infections differed (1.4% vs 1.0%), so most observational PPI harms look like residual confounding. GERD prevalence is up to six-fold higher at BMI above 35; about two-thirds of pregnant women have heartburn. No national prevalence figures are given (full text, PMC8754510; abstract, PMID 34807007). 10.14309/ajg.0000000000001538
- Lam, J. R., Schneider, J. L., Zhao, W., & Corley, D. A. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22), 2435-2442. In a large case-control study, two or more years of PPI use was associated with increased risk of vitamin B12 deficiency. 10.1001/jama.2013.280490
- Laine, L., DeVault, K., Katz, P., Mitev, S., Lowe, J., Hunt, B., & Spechler, S. (2023). Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology, 164(1), 61-71. 1,024 adults with erosive esophagitis randomized to vonoprazan 20 mg or lansoprazole 30 mg daily for up to 8 weeks. Healing by week 8: 92.9% vs 84.6% (difference 8.3%, 95% CI 4.5-12.2) - noninferior in the primary analysis, superior in the exploratory analysis. Healing of Los Angeles grade C/D esophagitis at week 2 was superior with vonoprazan (difference 17.6%, 95% CI 7.4-27.4); the abstract gives only the difference, not the two group rates. Heartburn-free days: noninferior only (difference 2.7%, 95% CI -1.6 to 7.0). In 878 patients, 24-week maintenance of healing was also superior with vonoprazan 10 or 20 mg. The authors say the benefit was seen predominantly in more severe erosive esophagitis; one author's affiliation is Phathom Pharmaceuticals (abstract, PMID 36228734). 10.1053/j.gastro.2022.09.041
- Shaheen, N. J., Falk, G. W., Iyer, P. G., Souza, R. F., Yadlapati, R. H., Sauer, B. G., & Wani, S. (2022). Diagnosis and management of Barrett's esophagus: an updated ACG guideline. American Journal of Gastroenterology, 117(4), 559-587. GRADE-based guideline. Suggests a single screening endoscopy for patients with chronic GERD symptoms and 3 or more additional risk factors for Barrett's esophagus (BE): male sex, age > 50 years, White race, tobacco smoking, obesity, and family history of BE or esophageal adenocarcinoma in a first-degree relative (conditional, very low quality). Annual cancer progression is estimated at 0.2%-0.05% for nondysplastic BE (NDBE) and approximately 0.7% for low-grade dysplasia (LGD). NDBE >= 3 cm is surveyed every 3 years and < 3 cm every 5 years (strong, moderate); indefinite for dysplasia: repeat endoscopy within 6 months after increasing PPI to twice daily; confirmed LGD under surveillance: endoscopy at 6 and 12 months, then annually. For confirmed LGD, endoscopic therapy is suggested, with surveillance an acceptable alternative (conditional, moderate), although the abstract says 'we recommend'. At least once-daily PPI in BE is suggested (conditional, very low). No recommendation on chemoprevention or routine biomarkers because of insufficient data (abstract, PMID 35354777; full text, PMC10259184). 10.14309/ajg.0000000000001680
- Jacobson, B. C., Somers, S. C., Fuchs, C. S., Kelly, C. P., & Camargo, C. A. (2006). Body-mass index and symptoms of gastroesophageal reflux in women. New England Journal of Medicine, 354(22), 2340-2348. Nurses' Health Study questionnaire, 10,545 women: dose-dependent rise in frequent reflux symptoms with BMI (OR 2.20 at BMI 25-27.4 and 2.92 at 30-34.9 vs 20-22.4); in normal-weight women a BMI increase > 3.5 went with OR 2.80. Observational; the abstract reports no weight-loss or nocturnal-reflux outcome (abstract, PMID 16738270). 10.1056/NEJMoa054391